StockData

Clinuvel Pharmaceuticals Ltd (CLVLF) stock

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30
$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

Earnings

Clinuvel Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Clinuvel Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Jun 30, 2026Aug 20, 2026before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Clinuvel Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Clinuvel Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Clinuvel Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. CUV | Nasdaq : CUVL | Börse Frankfurt: UR9
    6-K
  2. 6-K exhibit EX-99.1
    6-K
  3. 6-K exhibit EX-99.1
    6-K
  4. 6-K exhibit EX-99.2
    6-K
  5. 6-K exhibit EX-99.3
    6-K
  6. 6-K exhibit EX-99.1
    6-K
  7. response in vitiligo: new cases from the CUV105 trial presented to EADV
    6-K
  8. administration device for controlled-release formulations
    6-K
  9. 6-K exhibit EX-99.1
    6-K
  10. 6-K exhibit EX-99.2
    6-K
  11. 6-K exhibit EX-99.3
    6-K
  12. Annual Results – Investor Webinar
    6-K
  13. CUVL | Börse Frankfurt: UR9
    6-K
  14. CUV | Nasdaq : CUVL | Börse Frankfurt: UR9
    6-K
  15. CUV | Nasdaq : CUVL | Börse Frankfurt: UR9
    6-K

See a number that looks wrong?